Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CTA-derived biplane 3D roadmap fusion for catheter navigation in spinal angiography.

Journal of neuroradiology = Journal de neuroradiologie·2026
Same author

Biplane 3D roadmap-guided traversal of an occluded sinus for transvenous embolization of a TS-SS/marginal sinus dAVF.

Journal of neurointerventional surgery·2026
Same author

Strain-dependent disease progression and necrotizing granuloma formation in a murine model induced by virulent strains of <i>Mycobacterium avium</i> complex.

Microbiology spectrum·2026
Same author

Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

[Coil Embolization Strategy Based on Aneurysm Morphology: Roles of Framing, Filling, and Finishing Coils].

No shinkei geka. Neurological surgery·2026
Same author

<i>Mafb</i> deficiency in myeloid cells increases susceptibility to <i>Mycobacterium tuberculosis</i> infection in mice.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 12, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

Targeting STEAP1 as an anticancer strategy.

Hajime Nakamura1, Yohei Arihara1, Kohichi Takada1

  • 1Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Frontiers in Oncology
|November 1, 2023
PubMed
Summary

Six-transmembrane epithelial antigen of prostate 1 (STEAP1) is overexpressed in many cancers, making it a promising therapeutic target. New anticancer strategies targeting STEAP1 show potential for improved patient outcomes.

Keywords:
CAR-T therapySTEAP1antibody therapyanticancer strategiescancer vaccine

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.7K

Related Experiment Videos

Last Updated: Jul 12, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Six-transmembrane epithelial antigen of prostate 1 (STEAP1) was initially identified in prostate cancer.
  • STEAP1 overexpression is linked to poor prognosis across various cancer types.
  • STEAP1's tumor specificity and membrane localization present it as a viable therapeutic target.

Purpose of the Study:

  • To review the oncogenic functions of STEAP1 in different cancer types.
  • To explore STEAP1 as a target for novel anticancer strategies.
  • To provide insights into developing new therapies targeting STEAP1.

Main Methods:

  • Literature review of STEAP1's role in oncogenesis.
  • Analysis of clinical trial data for STEAP1-targeted therapies.
  • Evaluation of STEAP1 as a target for immunotherapies.

Main Results:

  • STEAP1 is overexpressed in multiple cancers, correlating with poor prognosis.
  • Phase 1 trials show clinical efficacy of antibody-drug conjugates targeting STEAP1.
  • STEAP1 is identified as a promising target for chimeric antigen receptor-T cell therapy.

Conclusions:

  • STEAP1 is a significant oncogenic factor with broad cancer relevance.
  • Targeting STEAP1 with antibody-drug conjugates and immunotherapies demonstrates therapeutic potential.
  • Further development of STEAP1-targeting anticancer strategies is warranted.